Formoterol
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
- Formoterol
- Formoterol: From Long-Acting Bronchodilation to Confirmed Use in Bronchitis, Obstructive Lung Disease, and Asthma
Formoterol: From Long-Acting Bronchodilation to Confirmed Use in Bronchitis, Obstructive Lung Disease, and Asthma
One-Sentence Summary
Formoterol (DrugBank DB00983) is a long-acting β2-adrenergic agonist (LABA) whose original indication data was not provided in this evidence pack, though it is clinically well known as a bronchodilator for obstructive airway disease. The TxGNN model returned six candidate indications for this drug; three are well supported by real clinical evidence (Bronchitis/COPD, Obstructive Lung Disease, Asthma — each with L1 evidence and dozens of Phase 3 RCTs), while the other three (Respiratory Malformation, Rienhoff Syndrome, Asthma-Susceptibility Trait) have little or no supporting evidence and are flagged in this pack itself as likely knowledge-graph label noise. Overall: strong signal for airway-obstruction indications, no signal for structural/genetic disease labels.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not provided in dataset (Formoterol is an established long-acting β2-agonist bronchodilator) |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Predicted Indications Screened | 6 |
| Highest TxGNN Score | Respiratory malformation — 99.92% (flagged as data noise, no supporting evidence) |
| Most Clinically Credible Predictions | Bronchitis (chronic/COPD), Obstructive Lung Disease, Asthma — all L1 evidence |
| Overall Recommended Decision | Proceed with Guardrails (bronchitis/COPD, obstructive lung disease, asthma) — Hold (respiratory malformation, Rienhoff syndrome, asthma-susceptibility trait) |
All Predicted Indications at a Glance
| Rank | Disease | TxGNN Score | Evidence Level | Decision Stage | Recommendation |
|---|---|---|---|---|---|
| 1 | Respiratory malformation | 99.92% | L4 | S0 | Hold |
| 2 | Bronchitis (chronic bronchitis/COPD) | 99.92% | L1 | S2 | Proceed with Guardrails |
| 3 | Rienhoff syndrome | 99.90% | L5 | S0 | Hold |
| 4 | Obstructive lung disease | 99.90% | L1 | S3 | Proceed with Guardrails |
| 5 | Asthma | 99.74% | L1 | S3 | Proceed with Guardrails |
| 6 | Asthma-related traits, susceptibility to | 99.50% | L5 | S0 | Hold |
Why Is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this dataset. Based on well-established pharmacology, Formoterol is a long-acting β2-adrenergic receptor agonist (LABA). It activates β2 receptors on airway smooth muscle, raising intracellular cAMP and producing sustained bronchodilation (onset within minutes, duration ~12 hours).
This mechanism explains why three of the six TxGNN predictions are mechanistically sound: Bronchitis (COPD phenotype), Obstructive Lung Disease, and Asthma are all conditions defined by reversible or partially reversible airflow limitation — exactly the physiological target of a LABA. This is corroborated by the evidence pack: dozens of completed Phase 3 RCTs (often as fixed-dose combinations with inhaled corticosteroids or LAMAs) already establish formoterol’s efficacy and safety in these exact populations, which is why these three predictions reach evidence level L1 and decision stage S2–S3.
The remaining three predictions are mechanistically implausible and are explicitly annotated as such in the source rationale:
- Respiratory malformation is a structural/congenital anomaly; a bronchodilator cannot correct anatomical defects. The clinical trials and literature returned for this label are actually asthma/COPD/Symbicort studies, indicating a knowledge-graph disease-label mismatch rather than a genuine signal.
- Rienhoff syndrome is a connective-tissue disorder linked to TGF-β signaling, with no known relationship to β2-adrenergic/cAMP pathways, and has zero supporting trials or literature.
- Asthma-related traits, susceptibility to describes genetic predisposition, not a treatable disease state — a bronchodilator addresses symptoms after onset, not underlying susceptibility, and again has zero supporting evidence.
Detailed Evidence — Credible Indications
1. Bronchitis (Chronic Bronchitis / COPD Phenotype) — L1, Proceed with Guardrails
Mechanistic note: Strong physiological basis for chronic bronchitis/COPD; weaker for acute (typically viral) bronchitis without airflow obstruction — this distinction should not be blurred in labeling.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01462942 | Phase 3 | Completed | 2,443 | Aclidinium/formoterol fixed-dose combination vs. components/placebo in stable COPD; large confirmatory maintenance bronchodilator trial |
| NCT01437397 | Phase 3 | Completed | 1,692 | Aclidinium bromide/formoterol fumarate fixed-dose combinations vs. monotherapies over 24 weeks in moderate-to-severe COPD |
| NCT00064415 | Phase 3 | Completed | 799 | Open-label chronic safety study of arformoterol over 12 months in COPD |
| NCT00064402 | Phase 3 | Completed | 741 | Multicenter RCT of (R,R)-formoterol (arformoterol) bronchodilator effect and safety in COPD |
| NCT01572792 | Phase 3 | Completed | 921 | Long-term extension study of aclidinium/formoterol combinations in moderate-to-severe COPD |
| NCT00250679 | Phase 3 | Completed | 443 | Long-term safety study of arformoterol tartrate inhalation solution BID in COPD |
| NCT06571942 | Phase 4 | Recruiting | 128 | Ongoing triple inhaled therapy vs. COPD/chronic bronchitis without obstruction from biomass exposure |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27916620 | 2017 | RCT | Chest | Efficacy/safety of glycopyrrolate/formoterol MDI (co-suspension technology) in COPD (PINNACLE-1/2) |
| 31920296 | 2019 | RCT | Int J Chron Obstruct Pulmon Dis | Long-term safety/efficacy of budesonide/glycopyrronium/formoterol MDI in Japanese COPD patients |
| 28821260 | 2017 | RCT | Respiratory Research | 24-hour bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol in COPD |
| 37696312 | 2023 | RCT | Respiratory Medicine | Tiotropium add-on to budesonide/formoterol in bronchiolitis obliterans post-HSCT |
| 20714376 | 2010 | Review | Int J Chron Obstruct Pulmon Dis | Review of nebulized formoterol (Perforomist) clinical efficacy and safety in COPD |
| 31015757 | 2019 | Meta-analysis | Int J Chron Obstruct Pulmon Dis | Comparative risks of budesonide/formoterol vs. placebo/monotherapy in stable COPD |
| 41654451 | 2026 | Pharmacovigilance | Clinical Therapeutics | Real-world adverse event analysis of budesonide/formoterol using FAERS/JADER/CVAR databases |
2. Obstructive Lung Disease — L1, Proceed with Guardrails
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04609878 | Phase 3 | Completed | 2,274 | Budesonide/glycopyrronium/formoterol vs. components/Symbicort in inadequately controlled asthma |
| NCT02345161 | Phase 3 | Completed | 1,811 | FF/UMEC/VI once-daily triple therapy vs. budesonide/formoterol twice-daily in COPD |
| NCT02676076 | Phase 3 | Completed | 1,153 | 52-week trial: extrafine beclometasone/formoterol/glycopyrronium vs. beclometasone/formoterol in uncontrolled asthma |
| NCT01911364 | Phase 3 | Completed | 3,686 | 52-week trial of beclometasone+formoterol+glycopyrrolate vs. tiotropium combinations in severe COPD |
| NCT00649025 | Phase 3 | Completed | 438 | Fluticasone/formoterol single-inhaler vs. fluticasone alone in moderate-to-severe asthma |
| NCT01908140 | Phase 3 | Completed | 933 | Aclidinium/formoterol vs. salmeterol/fluticasone over 24 weeks in symptomatic COPD |
Literature Evidence
Currently no related literature available (PubMed query returned 0 results for this disease label).
3. Asthma — L1, Proceed with Guardrails
Mechanistic/safety note: Formoterol’s β2-agonist mechanism is standard-of-care for asthma bronchodilation, but LABA monotherapy carries a known class-level warning for increased asthma-related mortality risk — it must be used in fixed combination with an inhaled corticosteroid (ICS), not alone. This is a critical guardrail for any repurposing pathway.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01444430 | Phase 3 | Completed | 12,460 | Large safety study evaluating serious asthma-related events: Symbicort (budesonide/formoterol) vs. ICS alone |
| NCT04609878 | Phase 3 | Completed | 2,274 | Efficacy/safety of budesonide/glycopyrronium/formoterol in inadequately controlled asthma |
| NCT03015259 | Phase 3 | Completed | 1,762 | Therapeutic equivalence of budesonide/formoterol inhaler vs. Symbicort reference in adult asthma |
| NCT02676076 | Phase 3 | Completed | 1,153 | 52-week superiority trial of triple vs. dual formoterol-containing combination in uncontrolled asthma |
| NCT00419952 | Phase 3 | Completed | 742 | 52-week safety comparison of Symbicort pMDI vs. budesonide alone in African American asthma patients |
| NCT00649025 | Phase 3 | Completed | 438 | Fluticasone/formoterol vs. fluticasone alone over 12 weeks in moderate-to-severe asthma |
| NCT05755906 | Phase 3 | Completed | 374 | Budesonide/formoterol MDI vs. budesonide MDI in inadequately controlled asthma (LITHOS) |
| NCT01676987 | Phase 3 | Completed | 181 | Single-capsule budesonide-formoterol combination vs. budesonide alone in uncontrolled asthma |
Literature Evidence
Currently no related literature available (PubMed query returned 0 results for this disease label).
Low-Confidence Predictions (Not Recommended to Pursue)
| Disease | Score | Evidence | Assessment |
|---|---|---|---|
| Respiratory malformation | 99.92% | L4, Hold | Trials/literature returned are actually asthma/COPD/Symbicort studies mismatched to this label; a bronchodilator cannot address structural anomalies. Judged as knowledge-graph label noise. |
| Rienhoff syndrome | 99.90% | L5, Hold | Zero trials, zero literature. Connective-tissue/TGF-β disorder with no known mechanistic link to β2-agonism. |
| Asthma-related traits, susceptibility to | 99.50% | L5, Hold | Zero trials, zero literature. Describes genetic predisposition, not a treatable disease state. |
India Market Information
Formoterol is currently not marketed in this jurisdiction (0 registrations on file). No license records are available to summarize.
Safety Considerations
Drug Interactions: A total of 462 interactions were identified (drug-level, not indication-specific); representative examples from the dataset include:
- Additive cardiovascular/sympathomimetic stimulation — Ephedrine, Ephedrine (nasal), Diethylpropion, Isometheptene (all Moderate)
- QT-prolongation risk — Cisapride, Dolasetron (both Moderate)
- CYP3A4 interaction — Clarithromycin (Moderate), may increase systemic formoterol exposure
- Antidiabetic agents — Acarbose, Albiglutide, Alogliptin, Canagliflozin, Chlorpropamide, Dapagliflozin, Dulaglutide, Empagliflozin (all Moderate) — β2-agonists can antagonize glycemic control and mask hypoglycemia symptoms
- Inhaled corticosteroids — Beclomethasone, Betamethasone, Budesonide, Dexamethasone (all Minor) — reflect expected therapeutic co-administration rather than a hazard
- Famotidine (Moderate)
Known class-level warning (from clinical literature, not the safety.key_warnings field): LABA monotherapy in asthma is associated with increased risk of asthma-related death; formoterol should not be used as asthma monotherapy without a concomitant ICS.
Detailed TFDA-equivalent label warnings and contraindications are not available in this dataset (blocking data gap — see Conclusion).
Conclusion and Next Steps
Decision: Proceed with Guardrails (for Bronchitis/COPD, Obstructive Lung Disease, and Asthma only) — Hold on Respiratory Malformation, Rienhoff Syndrome, and Asthma-Susceptibility Trait.
Rationale:
- Three of six predicted indications are backed by dozens of completed Phase 3 RCTs with large enrollments and a clear, well-established mechanistic rationale (L1 evidence, S2–S3 decision stage) — these represent genuine, high-confidence repurposing/label-expansion signals rather than novel discoveries, since formoterol is already a recognized therapy in these disease areas globally.
- The remaining three indications lack any credible clinical or literature support and are explicitly flagged in the underlying evidence as likely knowledge-graph label noise or mechanistically implausible; pursuing them would not be justified.
To proceed, the following is needed:
- Official TFDA/local regulatory label (warnings, contraindications) — currently a Blocking data gap (DG001) preventing safety pre-screening (S1)
- Formal mechanism-of-action documentation from DrugBank (currently a High-severity data gap, DG002)
- Clarification of “bronchitis” sub-phenotype (chronic/COPD-associated vs. acute viral) before any labeling claim, to avoid indication over-generalization
- Confirmation of LABA/ICS combination requirement in any asthma-related regulatory submission, given the class-level mortality warning
- Local market entry assessment, since the drug currently holds zero registrations in this jurisdiction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.